He Jiankui, a biophysicist known for creating the first gene-edited babies, has been released from prison, where he served time for his controversial genetic experiments. In 2018, He edited the genomes of three embryos with the aim of providing resistance to HIV, actions that led to global outrage and a three-year prison sentence for illegal medical practices.
Following his release, He Jiankui is seeking to apply similar gene-editing techniques to address Alzheimer’s disease. Despite the potential benefits, his proposed germline editing methods remain prohibited in many countries and mirror the controversial practices that resulted in his previous legal troubles. Reports indicate that he is currently fundraising to introduce a genetic mutation found in some Icelandic individuals who are known to be free of Alzheimer’s and enjoy longer lifespans.
Plans for Animal Trials and Future Human Tests
He has made it clear that he intends to begin testing on animals, as noted by the *Daily Star*. While this initial phase may be more straightforward, conducting human trials will likely present significant challenges. Experts suggest that He may find opportunities to conduct such trials in South Africa, where germline gene editing received legal approval in 2022, according to *NewsBytes*.
He Jiankui first garnered international attention for his announcement at a conference, where he claimed to have modified a gene in embryos that were later brought to term. His actions sparked intense debate over ethical considerations, consent, and safety, leading to widespread condemnation from the global scientific community.
The Evolution of Gene-Editing Technologies
As gene-editing technologies continue to evolve, there is a growing consensus in the biomedicine field that while gene editing could revolutionize treatments for existing conditions, editing embryos for reproductive purposes—especially for complex diseases like Alzheimer’s—remains a contentious issue. Somatic therapies, which do not affect eggs, sperm, or embryos, are gaining regulatory approvals for serious diseases, highlighting a clear division in the acceptable use of gene-editing technologies.
In summary, He Jiankui’s release and his intentions to pursue further genetic research raise significant ethical and regulatory questions. His previous actions have left a lasting impact on the field of genetic research, and his future endeavors will be closely monitored by both supporters and critics.
